Eczema treatment is in the middle of a genuine revolution. For most of the twentieth century, patients with moderate-to-severe atopic dermatitis had essentially one category of treatment: corticosteroids. They worked, but carried real limitations with long-term use, and for many patients they didn't work well enough. Then, in just eight years, the field changed dramatically. Since 2017, five or more new FDA-approved therapies—including the first biologic specifically designed for atopic dermatitis, three JAK inhibitors, and additional targeted agents—have transformed what "managing eczema" can actually mean. For the 31.6 million Americans living with this condition, that is a profound shift.
What Is Eczema?
Atopic dermatitis—commonly called eczema—is a chronic, inflammatory skin condition characterized by intensely itchy, dry, red, and sometimes blistered or weeping skin. It is not an allergy itself, but it is part of the "atopic triad" alongside allergic rhinitis (hay fever) and asthma, and people with one condition are significantly more likely to have the others.
Eczema is immune-mediated, meaning the immune system is fundamentally involved in driving inflammation. It is also a disease of skin barrier dysfunction—the outer layer of skin in atopic dermatitis patients does not hold moisture or keep out irritants and allergens as effectively as it should. Approximately 31.6 million Americans are affected, including up to 20% of children and 3% of adults. While it often begins in infancy or early childhood, a substantial number of patients develop adult-onset eczema or carry their childhood disease into adulthood. The economic burden is estimated at $5.9 billion annually in the United States when direct medical costs and lost productivity are combined.
The Skin Barrier Theory: Why It Matters for Treatment
One of the pivotal advances in understanding eczema came with the discovery of filaggrin. Filaggrin is a structural protein that plays a critical role in building and maintaining the skin's outermost protective layer, the stratum corneum. In atopic dermatitis, filaggrin gene mutations are extremely common—present in roughly 30% of European-descent patients with the condition—and they result in a compromised skin barrier.
When the skin barrier is impaired, two things happen simultaneously: moisture escapes from within the skin (transepidermal water loss), causing dryness and vulnerability, and allergens, irritants, and microbes from the external environment penetrate into the skin more easily. This triggers immune activation, which drives inflammation, which damages the barrier further—a vicious cycle. Bacteria like Staphylococcus aureus, which colonize the skin of most eczema patients, further amplify this inflammatory response.
Critically, the specific immune pathways involved are now well understood. The Th2 immune pathway—regulated by cytokines including interleukin-4 (IL-4), interleukin-13 (IL-13), and interleukin-31 (IL-31)—is the primary driver of atopic inflammation. This understanding is precisely what enabled the development of targeted biologics. If you know which immune signals are causing the problem, you can design a therapy to block exactly those signals.
Traditional Treatments and Their Limitations
Before discussing the new options, it's worth understanding what was available before—and why many patients were inadequately managed.
Topical corticosteroids remain the most commonly prescribed treatment for eczema and are genuinely effective for most patients with mild-to-moderate disease. They reduce inflammation, relieve itch, and are inexpensive. However, long-term continuous use on sensitive skin areas carries risks: skin thinning (atrophy), stretch marks, telangiectasias (broken blood vessels visible through the skin), and, with extensive body surface use, systemic absorption with potential effects on cortisol levels. Patients using steroids on the face or skin folds require particular caution. For patients with chronic moderate-to-severe disease, these limitations mean steroids alone are often insufficient for long-term control.
Topical calcineurin inhibitors—tacrolimus (Protopic) and pimecrolimus (Elidel)—offer a steroid-free option that can be used on the face and sensitive areas without risk of skin thinning. They work by suppressing T-cell activation in the skin. They are effective in many patients but can cause a burning sensation, particularly in the first weeks of use, and historically carried an FDA black box warning about a theoretical lymphoma risk that subsequent evidence has not substantiated. They are often used as "steroid-sparing" maintenance treatments on sensitive areas.
Phototherapy, particularly narrowband UVB (NB-UVB) light therapy, is an established and effective treatment for moderate-to-severe eczema. It works by suppressing the inflammatory immune response in the skin and has an excellent long-term safety profile. The primary limitation is practical: patients typically need to attend a dermatology office two to three times per week for several months, which is a significant burden. Dermatology of Seattle offers on-site UVB phototherapy at our Burien and Bellevue locations.
Cyclosporine and methotrexate are systemic immunosuppressants used off-label for severe eczema but carry significant side effect profiles and require regular lab monitoring. They have largely been supplanted by the newer targeted therapies in patients eligible for systemic treatment.
The Biologic Revolution: Dupixent and Beyond
The approval of dupilumab (brand name: Dupixent) by the FDA in 2017 was a watershed moment in dermatology. Dupilumab is a fully human monoclonal antibody that blocks the shared receptor for IL-4 and IL-13—the two cytokines most responsible for driving the Th2 immune cascade in atopic dermatitis. By interrupting these specific signals, dupilumab reduces inflammation without broadly suppressing the immune system the way older systemic agents did.
The clinical results were striking. In pivotal trials, approximately 70% of patients treated with dupilumab achieved an Eczema Area and Severity Index (EASI) score improvement of 75% or more—meaning their disease was at least 75% less severe after treatment. About 38% achieved EASI-90, a near-complete or complete response. Itch—often the most disabling symptom—improved dramatically within the first two weeks in many patients. Dupilumab is administered by subcutaneous injection every two weeks (after a loading dose) and has an excellent long-term safety profile, with no required lab monitoring and no systemic immunosuppression. The most common side effect is conjunctivitis (eye inflammation), which occurs in a minority of patients and is manageable.
Dupilumab was later approved for adolescents and children as young as 6 months with moderate-to-severe atopic dermatitis, as well as for asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis—reflecting its broad anti-Th2 mechanism across atopic diseases.
Two additional IL-13-specific biologics have since been approved. Tralokinumab (Adbry, approved 2021) blocks IL-13 only, rather than both IL-4 and IL-13, and is also administered every two weeks initially, then monthly in responding patients. Lebrikizumab (Ebglyss, approved 2023) is another IL-13 blocker with a similar profile and a monthly maintenance dosing option. These newer agents offer additional choices for patients who may not respond optimally to dupilumab or who prefer a different dosing schedule.
JAK Inhibitors: A Different Mechanism, Faster Onset
JAK inhibitors represent a second class of new targeted therapy for atopic dermatitis, distinct from biologics in both their mechanism and their delivery. While biologics are large proteins that block specific cytokines outside the cell, JAK inhibitors are small molecules taken orally or applied topically that work inside the cell, blocking the Janus kinase (JAK) enzymes that many immune signaling pathways depend on.
Upadacitinib (Rinvoq, approved 2022 for AD) is a selective JAK1 inhibitor taken as a once-daily oral tablet. In head-to-head trials against dupilumab, upadacitinib demonstrated faster onset of itch relief—with significant improvement as early as week 1—and achieved numerically higher rates of EASI-75 response in some studies. It is approved for moderate-to-severe atopic dermatitis in adults and adolescents.
Abrocitinib (Cibinqo, approved 2022) is another selective JAK1 oral inhibitor with a similar efficacy profile, also approved for adults with moderate-to-severe disease.
Ruxolitinib cream (Opzelura, approved 2021) is a topical JAK1/JAK2 inhibitor—an important distinction. As a topical, it acts locally in the skin with minimal systemic absorption, making its safety profile substantially different from the oral JAK inhibitors. It is approved for short-term and non-continuous longer-term use in mild-to-moderate atopic dermatitis in patients 12 and older, and represents a non-steroidal topical option with a different mechanism than calcineurin inhibitors.
The oral JAK inhibitors (Rinvoq and Cibinqo) carry an FDA boxed warning—the agency's strongest warning type—noting risks of serious infections, malignancy, major adverse cardiovascular events, thrombosis, and mortality. These risks were established in a large trial in rheumatoid arthritis patients using tofacitinib (a less selective JAK inhibitor) and were extrapolated to the class as a whole. In practice, most dermatology patients with eczema are younger and healthier than the RA trial population, and dermatologists prescribe these agents after a careful benefit-risk discussion, especially in patients over 50 or with cardiovascular risk factors. The boxed warning is context that matters—but it should not preclude a thoughtful conversation about whether a JAK inhibitor is appropriate for a given patient.
Is Biologic or JAK Inhibitor Therapy Right for You?
Not everyone with eczema needs a biologic or JAK inhibitor. These therapies are generally considered for patients with moderate-to-severe atopic dermatitis—defined as disease affecting a meaningful portion of the body surface area, causing significant itch, sleep disruption, or quality of life impairment, and that has not been adequately controlled with optimized topical therapies and/or phototherapy.
The shared decision-making conversation with your dermatologist will typically cover:
- The severity and extent of your disease and how it affects your daily life
- What you've tried before and how well it worked
- Your personal health history and any contraindications
- Your preference for injections versus oral tablets
- Insurance coverage and prior authorization requirements
On the question of insurance: the good news is that coverage for dupilumab and the approved JAK inhibitors has improved substantially since their launch. Most major commercial insurance plans and Medicare Part D cover these medications for atopic dermatitis, though prior authorization is nearly always required. Prior authorization means your dermatologist must document that you have moderate-to-severe disease and that you have tried and failed or have contraindications to first-line therapies. Patient assistance programs are also available from the manufacturers for eligible patients who face affordability barriers.
Eczema Triggers in the Pacific Northwest
Living in the Seattle area means navigating a specific set of environmental triggers that can worsen eczema, and understanding them is an important part of management alongside any medical therapy.
Cold, dry winters. Pacific Northwest winters, particularly in the greater Seattle area, bring extended periods of cold air that holds less moisture. Indoor heating further dries the air. Low ambient humidity dramatically accelerates transepidermal water loss in already-compromised skin, making winter the most challenging season for most eczema patients. Running a humidifier, applying emollients immediately after bathing, and switching to thicker ointment-based moisturizers in colder months can all help.
Humidity swings. The Pacific Northwest can see significant humidity variation—warm, dry summers contrast with wet winters—and these transitions are often when patients experience flares. The skin's barrier needs time to adapt, and rapid environmental changes can outpace it.
Regional outdoor allergens. The Pacific Northwest has high levels of alder and birch pollen in spring, a significant mold burden year-round due to rainfall, and grass pollens in summer. Patients with eczema who also have allergic rhinitis or asthma may notice skin flares correlating with high pollen days. While eczema is not a contact allergy to pollen, systemic allergic sensitization can amplify skin inflammation through immune mechanisms.
Lifestyle triggers. Fragrance is one of the most common contact sensitizers for eczema patients—laundry detergents, fabric softeners, and personal care products labeled "unscented" or "natural" may still contain botanicals that trigger reactions. Wool and synthetic fabrics can also be mechanical irritants. Stress—something urban Pacific Northwest life supplies in abundance—is a well-established eczema trigger that works through neuroimmune pathways to amplify skin inflammation.
Comprehensive Eczema Care at Dermatology of Seattle
At Dermatology of Seattle, we treat atopic dermatitis across the full spectrum of severity, from newly diagnosed mild disease to long-standing, difficult-to-control cases that have failed multiple prior therapies. Our approach is individualized: we do not have a one-size-fits-all protocol, because eczema does not behave the same way in every patient.
For mild disease, we optimize topical therapy—prescribing the right corticosteroid potency for the right location, introducing non-steroidal topicals like tacrolimus or ruxolitinib cream for maintenance and sensitive areas, and building a personalized skincare and moisturization plan.
For moderate disease, we offer on-site narrowband UVB phototherapy—a highly effective, medication-free systemic option available at both our Burien and Bellevue offices. For patients who are candidates and have time in their schedules, phototherapy can achieve excellent and durable control.
For moderate-to-severe disease, we have full prescribing experience with dupilumab (Dupixent), tralokinumab (Adbry), lebrikizumab (Ebglyss), upadacitinib (Rinvoq), and abrocitinib (Cibinqo). We manage the prior authorization process, coordinate with pharmacies and specialty pharmacy teams, and monitor patients throughout treatment. We are committed to helping patients access therapies that were not available even a decade ago and that can genuinely change quality of life.
Learn more about our full eczema treatment services or explore our medical dermatology capabilities. When you're ready to talk to one of our board-certified dermatologists, scheduling an appointment is the first step toward better skin health.
Key Takeaways: What Has Changed for Eczema Patients
The landscape of atopic dermatitis treatment in 2026 looks fundamentally different from what was available in 2015. Patients who were told they had to "just manage" their eczema with steroids now have access to targeted biologics that block specific immune pathways driving their disease, JAK inhibitors that can provide rapid itch relief, and a topical JAK inhibitor that avoids systemic exposure entirely. Clinical trials demonstrate that approximately 70% of patients on dupilumab achieve meaningful disease improvement, and JAK inhibitors in some studies show even faster onset of action.
If you or a family member has eczema that is not adequately controlled—still waking up at night from itching, still missing work or school, still avoiding activities because of skin flares—it is worth asking your dermatologist whether one of these newer therapies might be appropriate. The answer may surprise you.